17,006 Shares in Amgen Inc. $AMGN Purchased by Leuthold Group LLC

Leuthold Group LLC bought a new stake in shares of Amgen Inc. (NASDAQ:AMGN) in the third quarter, Holdings Channel.com reports. The firm bought 17,006 shares of the medical research company’s stock, valued at approximately $4,799,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of AMGN. Mitchell Capital Management Co. bought a new stake in shares of Amgen during the third quarter valued at approximately $201,000. Eubel Brady & Suttman Asset Management Inc. bought a new stake in Amgen during the 3rd quarter valued at $1,246,000. LSV Asset Management raised its stake in Amgen by 10.7% during the 3rd quarter. LSV Asset Management now owns 333,290 shares of the medical research company’s stock valued at $94,054,000 after acquiring an additional 32,190 shares in the last quarter. Onyx Bridge Wealth Group LLC boosted its position in Amgen by 15.7% during the 3rd quarter. Onyx Bridge Wealth Group LLC now owns 1,780 shares of the medical research company’s stock worth $502,000 after acquiring an additional 242 shares during the period. Finally, Plan A Wealth LLC grew its stake in shares of Amgen by 11.8% in the third quarter. Plan A Wealth LLC now owns 1,158 shares of the medical research company’s stock worth $327,000 after purchasing an additional 122 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Insider Transactions at Amgen

In other news, SVP Nancy A. Grygiel sold 3,139 shares of the stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $337.26, for a total value of $1,058,659.14. Following the completion of the sale, the senior vice president owned 7,225 shares in the company, valued at $2,436,703.50. This represents a 30.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.76% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

AMGN has been the topic of a number of recent analyst reports. Scotiabank initiated coverage on shares of Amgen in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $385.00 price objective on the stock. Wall Street Zen downgraded shares of Amgen from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 7th. Deutsche Bank Aktiengesellschaft increased their price objective on shares of Amgen from $285.00 to $295.00 and gave the company a “hold” rating in a report on Thursday, February 5th. UBS Group boosted their target price on Amgen from $380.00 to $390.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Finally, Daiwa Securities Group upped their target price on Amgen from $370.00 to $410.00 and gave the stock an “outperform” rating in a research report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $354.04.

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $366.58 on Thursday. The stock has a fifty day moving average of $336.16 and a 200-day moving average of $312.77. The company has a market capitalization of $197.40 billion, a PE ratio of 25.76, a price-to-earnings-growth ratio of 3.73 and a beta of 0.46. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. Amgen Inc. has a one year low of $261.43 and a one year high of $385.12.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The firm had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. During the same quarter in the previous year, the company earned $5.31 EPS. The business’s revenue for the quarter was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, equities analysts anticipate that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 13th will be paid a $2.52 dividend. The ex-dividend date of this dividend is Friday, February 13th. This represents a $10.08 dividend on an annualized basis and a yield of 2.7%. This is a positive change from Amgen’s previous quarterly dividend of $2.38. Amgen’s dividend payout ratio (DPR) is 66.90%.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.